These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The role of nicotinic acetylcholine receptors in Alzheimer's disease. Oddo S; LaFerla FM J Physiol Paris; 2006; 99(2-3):172-9. PubMed ID: 16448808 [TBL] [Abstract][Full Text] [Related]
23. Nicotine an efficient tool of the neurobiological research today, the tool of treatment tomorrow? Riljak V; Langmeier M Prague Med Rep; 2005; 106(4):329-48. PubMed ID: 16572927 [TBL] [Abstract][Full Text] [Related]
28. Nicotinic cholinergic antagonists: a novel approach for the treatment of autism. Lippiello PM Med Hypotheses; 2006; 66(5):985-90. PubMed ID: 16406687 [TBL] [Abstract][Full Text] [Related]
29. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Koutsilieri E; Riederer P Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259 [TBL] [Abstract][Full Text] [Related]
30. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Potter AS; Newhouse PA; Bucci DJ Behav Brain Res; 2006 Dec; 175(2):201-11. PubMed ID: 17081628 [TBL] [Abstract][Full Text] [Related]
31. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors. Hogg RC; Bertrand D Biochem Pharmacol; 2007 Feb; 73(4):459-68. PubMed ID: 16979139 [TBL] [Abstract][Full Text] [Related]
33. Nicotinic acetylcholine receptors: from structure to brain function. Hogg RC; Raggenbass M; Bertrand D Rev Physiol Biochem Pharmacol; 2003; 147():1-46. PubMed ID: 12783266 [TBL] [Abstract][Full Text] [Related]
34. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Pauly JR; Charriez CM; Guseva MV; Scheff SW Ann N Y Acad Sci; 2004 Dec; 1035():316-34. PubMed ID: 15681815 [TBL] [Abstract][Full Text] [Related]
35. Muscarinic acetylcholine receptors as CNS drug targets. Langmead CJ; Watson J; Reavill C Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893 [TBL] [Abstract][Full Text] [Related]
36. Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies. Nemeroff CB; Bissette G Prog Clin Biol Res; 1985; 192():333-41. PubMed ID: 2934745 [TBL] [Abstract][Full Text] [Related]
37. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Newhouse P; Singh A; Potter A Curr Top Med Chem; 2004; 4(3):267-82. PubMed ID: 14754447 [TBL] [Abstract][Full Text] [Related]
38. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Janhunen S; Ahtee L Neurosci Biobehav Rev; 2007; 31(3):287-314. PubMed ID: 17141870 [TBL] [Abstract][Full Text] [Related]
39. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Ward RJ; Lallemand F; de Witte P; Dexter DT Prog Neurobiol; 2008 Jun; 85(2):135-47. PubMed ID: 18482793 [TBL] [Abstract][Full Text] [Related]